Skip to main content
. 2022 Jul 15;77(4):1287–1302. doi: 10.1002/hep.32631

FIGURE 3.

FIGURE 3

Apolipoprotein F (APOF) overexpression decreases plasma triglyceride (TG) levels and simultaneously favors liver secretion and clearance of TG. (A) Hepatic human APOF, mouse Apof mRNA, and western blot for plasma human ApoF in Ad‐GFP or adenoviral overexpression of human ApoF (Ad‐hApoF) mice (n = 8–9 per group). (B) Plasma TG, fractionated pooled plasma TG by fast‐protein liquid chromatography and plasma ApoB in 5‐h fasted adenovirus‐expressed green fluorescent protein (Ad‐GFP) or Ad‐hApoF mice (n = 8–9 per group). (C) Plasma TG, calculation of TG production, and fractional catabolic rate following intra‐peritoneal injection with poloxamer 407 (P407; 1 g/kg bodyweight) (n = 8–9 per group). (D) Plasma TG/ApoB ratio 3 h after P407 injection in Ad‐GFP or Ad‐hApoF mice (n = 8–9 per group). (E) Hepatic TG content 3 h after P407 injection in Ad‐GFP or Ad‐hApoF mice (n = 8–9 per group). (F) Plasma FFA in 5‐h fasted Ad‐GFP or Ad‐hApoF mice (n = 8–9 per group). FCR, fractional catabolic rate; VLDL, very low density lipoprotein. *p < 0.05, **p < 0.01, ***p < 0.001 as compared to the control by t test, Mann–Whitney test or two‐way ANOVA as appropriate. Multiple comparisons were assessed by Fisher's least significant difference post hoc test for (C). All data are shown as the means ± SEM.